Australia

Found 8,137 articles

• Opthea to Participate in EF Hutton Hosted Discussion on OPT-302 and the Wet AMD Market

  5/17/2023

  Opthea Limited announced that Elemer Piros, Senior Biotechnlogy Analyst at EF Hutton will host a webinar with Dr. Megan Baldwin, CEO and Managing Director and Timothy E. Morris, CFO of Opthea Limited on Thursday, May 18th at 5:00 pm EDT.

• Immutep Receives Positive Feedback from FDA on Late-Stage Clinical Development of Eftilagimod Alpha in Non-Small Cell Lung Cancer

  5/16/2023

  Immutep Limited today announces it has received positive feedback from the US Food and Drug Administration (FDA), regarding the Company’s late-stage clinical development plans for its first-in-class soluble LAG-3 protein and MHC Class II agonist, eftilagimod alpha (“efti”), for the treatment of 1st line non-small cell lung cancer (NSCLC).

• AVITA Medical Reports First Quarter 2023 Financial Results and Affirms Full Year Guidance

  5/11/2023

  AVITA Medical, Inc., a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, reported financial results for the first quarter March 31, 2023.

• Alterity Therapeutics Enrolls First Patient in Australia in ATH434 Global Phase 2 Clinical Trial in Multiple System Atrophy

  5/10/2023

  Alterity Therapeutics today announced the first participant in Australia has been treated in the Company’s Phase 2 clinical trial of ATH434 in Multiple System Atrophy (MSA), a rare and highly debilitating Parkinsonian disorder.

• Appendix 4C – Q3 FY23 Quarterly Cash Flow Report

  5/10/2023

  Alterity Therapeutics Limited released its Appendix 4C Quarterly Cash Flow Report and update on company activities for the quarter ending 31st March 2023 (Q3 FY23).

• Radiopharm Theranostics Receives FDA Orphan Drug Designation for Trivehexin (RAD 301) in Pancreatic Cancer

  5/9/2023

  Radiopharm Theranostics is pleased to announce that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation to Ga68-Trivehexin (RAD 301) radiopharmaceutical technology for imaging of patients with pancreatic ductal adenocarcinoma (PDAC).

• Immutep to Participate in the JMP Securities Life Sciences Conference 2023

  5/9/2023

  Immutep Limited announces its management will present and be available for 1-on-1 meetings at the JMP Securities Life Sciences Conference, on Tuesday, May 16th, 2023.

• Industry Survey Identifies Successful Biotech Clinical Trial Strategies

  5/9/2023

  Novotech, the leading Asia Pacific centred biotech CRO conducted a survey of global biotech professionals, in partnership with Citeline, on their current and future clinical pipeline prospects, the main challenges of clinical trials, and perspective shifts regarding study locations.

• Immuron Announces FDA Removed Clinical Hold on New Campylobacter ETEC Therapeutic Paves way for Clinical Trial Initiation

  5/8/2023

  Immuron Limited is pleased to announce that the US Naval Medical Research Center has received approval from the US Food and Drug Administration to proceed with the clinical evaluation of a new oral therapeutic targeting Campylobacter and Enterotoxigenic Escherichia coli developed in collaboration with Immuron.

• Opthea To Present at the JMP Securities Life Sciences Conference

  5/8/2023

  Opthea Limited announced that Timothy E. Morris, the Company’s Chief Financial Officer will present at the JMP Securities Life Sciences Conference being held in New York City on May 15-16 2023.

• Telix to Supply Bayer with Illuccix® for Global Phase III Prostate Cancer Study

  5/7/2023

  Telix Pharmaceuticals Limited announces that it has entered into an agreement with Bayer AG to supply Illuccix® [1] for the Phase III ARASTEP study.

• BCAL DIAGNOSTICS OPENS NEW LABORATORY IN SYDNEY AS IT ACCELERATES DEVELOPMENT OF ITS BREAST CANCER BLOOD SCREENING TOOL

  5/4/2023

  BCAL Diagnostics Limited (ASX:BDX) (BCAL or Company) an Australian-based biotechnology company announced the opening of its development and clinical service laboratory in Sydney.

• Incannex Company Presentation – Results from Phase 1 Clinical Trial to Assess Proprietary IHL-675A

  5/3/2023

  Incannex Healthcare Ltd is pleased to announce a company presentation containing data and analysis of the results from the Phase 1 clinical trial undertaken to assess safety and pharmacokinetics of IHL-675A as an anti-inflammatory drug candidate.

• Immuron CEO, Steven Lydeamore to present at Coffee Microcaps

  5/2/2023

  Immuron Limited, an Australian based and globally integrated biopharmaceutical company that has developed two commercially available oral immunotherapeutic products for the treatment of gut mediated diseases, is pleased to provide a copy of the presentation being made in Melbourne at Coffee Microcaps Conference by our Chief Executive Officer, Steven Lydeamore.

• Immutep Announces KOL Event Focused on Eftilagimod Alpha in Non-Small Cell Lung Cancer and Head & Neck Squamous Cell Carcinoma

  5/2/2023

  Immutep Limited (ASX: IMM; NASDAQ: IMMP), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces a Key Opinion Leader (KOL) event will be hosted by Ladenburg Thalmann & Co, Inc., on Tuesday, May 9, 2023, from 11:30 AM – 1:00 PM ET.

• Immutep Receives Approval to Initiate INSIGHT-005 Trial Evaluating Eftilagimod Alpha and Anti-PD-L1 Therapy BAVENCIO®

  5/1/2023

  Immutep Limited announces it has received regulatory approval from the Paul-Ehrlich-Institut, German Federal Institute for Vaccines and Biomedicines, to initiate INSIGHT-005, an investigator-initiated, open-label Phase I trial evaluating the safety and efficacy of eftilagimod alpha in combination with BAVENCIO® in up to 30 patients with metastatic urothelial carcinoma.

• First Patients in Canada Imaged with Illuccix®: Now Commercially Available Nationwide

  5/1/2023

   Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces first patients have been imaged in Canada with its commercially available prostate cancer imaging agent, Illuccix® [kit for the preparation of gallium (68Ga) PSMA-11 for intravenous injection].

• Carina Biotech to Present Details of Planned Phase 1/2a Clinical Trial of LGR5-Targeted CAR-T Cell Therapy Candidate CNA3103 for Metastatic Colorectal Cancer at 2023 ASCO Annual Meeting

  5/1/2023

  Carina Biotech (Carina) today announced a poster presentation showcasing its planned Phase 1/2a clinical trial of its LGR5-targeted CAR-T cell therapy candidate CNA3103 in patients with metastatic colorectal cancer (mCRC) at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting that will take place in Chicago, Illinois on June 2-6.

• New Publication Validates geneType for Melanoma Risk Assessment

  4/28/2023

  Genetic Technologies Limited is pleased to announce the publication of a research paper in the peer-reviewed journal Melanoma Research validating the geneType for Melanoma risk assessment test in one of the most commonly diagnosed cancers in the Western world, 3rd in Australia and 5th in the United States.

• Quarterly Activities and Cashflow Report

  4/28/2023

  Bionomics Limited, a clinical-stage biopharmaceutical company developing novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system disorders with high unmet medical need, released its Appendix 4C – Quarterly Cashflow Report.